NewcelXNCEL +0.52%33 PB Ratio is 2.56 as of Jul. 06, 2026. GuruFocus rates NCEL with a GF Score™ of 33/100. The stock has 4 warning signs investors should review. Among 1,230 Biotechnology companies, NewcelX ranks better than 56.67% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-06), NewcelX's share price is $3.87. NewcelX's Book Value per Share for the quarter that ended in Dec. 2025 was $1.51. Hence, NewcelX's PB Ratio of today is 2.56.
The historical rank and industry rank for NewcelX's PB Ratio or its related term are showing as below:
NCEL'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 2.8
Current: 2.56
During the past 13 years, NewcelX's highest PB Ratio was 2.80. The lowest was 0.00. And the median was 0.00.
NCEL's PB Ratio is ranked better than 56.67% of 1230
companies
in the Biotechnology industry
Industry Median: 2.99
vs NCEL: 2.56
During the past 3 years, the average Book Value Per Share Growth Rate was 247.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of NewcelX was 247.40% per year. The lowest was -7.30% per year. And the median was 31.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
NewcelX PB Ratio Related Terms
NewcelX PB Ratio Historical Data
* Premium members only.
The historical data trend for NewcelX's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NewcelX's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NewcelX PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NewcelX's PB Ratio distribution charts can be found below:
* The bar in red indicates where NewcelX's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
NewcelX's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
NewcelX (NCEL) has a PB Ratio of 2.56 as of Jul. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NewcelX and its competitors. According to the industry distribution chart, NewcelX ranks #533 out of 1230 companies in the Biotechnology industry, placing it in the top 43.3%.
Is NewcelX's PB Ratio too high?
NewcelX's current PB Ratio is 2.56. The Biotechnology industry median PB Ratio is 2.99. NewcelX's value of 2.56 is 14.4% below this industry median. Based on the distribution chart, NewcelX ranks #533 out of 1230 companies in the Biotechnology industry, which is above the industry midpoint. Overall, NewcelX has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does NewcelX's PB Ratio compare to LPCN and PTN?
According to the Biotechnology industry distribution chart, NewcelX ranks #533 out of 1230 companies for PB Ratio. This puts NewcelX in the upper half of its industry. The industry median PB Ratio is 2.99. NewcelX's value of 2.56 is 14.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.99, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NewcelX's current PB Ratio of 2.56 is 14.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NewcelX and its competitors. For the Biotechnology industry, the median PB Ratio is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewcelX's current PB Ratio is 2.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewcelX stock overvalued right now?
NewcelX (NCEL) has a current PB Ratio of 2.56. The current PB Ratio is 2.56 and 14.4% below the Biotechnology industry median of 2.99. NewcelX's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For NewcelX (NCEL), the current PB Ratio is 2.56 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
33GF Score
Get the complete analysis for NCEL
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NCEL has been successfully added to your 
